Evidence map›Paper›PMID 28156095›Full record

ArticleBioconjugate chemistry2017

Optimized Translocator Protein Ligand for Optical Molecular Imaging and Screening.

Jun Li, Jarrod A Smith, Eric S Dawson, Allie Fu, Michael L Nickels, Michael L Schulte, H Charles Manning

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Potential of [Pharmaceutics · 2022
    Article
  3. Article
  4. TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun LiInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
Jarrod A SmithInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
Eric S DawsonInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
Allie FuInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
Michael L NickelsInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
Michael L SchulteInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.
H Charles ManningInterdisciplinary Materials Science Program, ∥Vanderbilt University Center for Structural Biology, and ■Department of Biomedical Engineering, Vanderbilt University , Nashville, Tennessee 37232, United States.ORCID 0000-0002-5057-4518

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
TSPO Ligands for Cancer ImagingR01CA163806 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MANNING, HENRY CHARLES · 2012 to 2016
$2.2M
Synergizing Quantitative HTS Technologies to Guide MIA Discovery and DevelopmentK25CA127349 · NCI · VANDERBILT UNIVERSITY · PI MANNING, HENRY CHARLES · 2008 to 2012
$709k
NCI NIH HHS K25 CA127349NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA163806NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

Translocator protein (TSPO) is a validated target for molecular imaging of a variety of human diseases and disorders. Given its involvement in cholesterol metabolism, TSPO expression is commonly elevated in solid tumors, including glioma, colorectal cancer, and breast cancer. TSPO ligands capable of detection by optical imaging are useful molecular tracers for a variety of purposes that range from quantitative biology to drug discovery. Leveraging our prior optimization of the pyrazolopyrimidine TSPO ligand scaffold for cancer imaging, we report herein a new generation of TSPO tracers with superior binding affinity and suitability for optical imaging and screening. In total, seven candidate TSPO tracers were synthesized and vetted in this study; the most promising tracer identified (29, K

Indexed as

AnimalsCell Line, TumorHumansLigandsMicroscopy, ConfocalModels, MolecularMolecular ImagingOptical ImagingProtein BindingRatsReceptors, GABALigandsReceptors, GABATSPO protein, human

Identifiers

PMID28156095
PMCPMC12097374

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.